238 related articles for article (PubMed ID: 34670399)
21. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report.
Guven DC; Kilickap S; Yildirim HC; Ceylan F; Bas O; Dizdar O
J Oncol Pharm Pract; 2021 Jul; 27(5):1281-1283. PubMed ID: 33070764
[TBL] [Abstract][Full Text] [Related]
22. Ewing sarcoma.
Eaton BR; Claude L; Indelicato DJ; Vatner R; Yeh B; Schwarz R; Laack N
Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28355. PubMed ID: 33818887
[TBL] [Abstract][Full Text] [Related]
23. Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells.
Visser LL; Bleijs M; Margaritis T; van de Wetering M; Holstege FCP; Clevers H
Cancer Res Commun; 2023 Oct; 3(10):2158-2169. PubMed ID: 37823774
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Ewing sarcoma of the head and neck: A retrospective survival analysis.
Martin E; Radomski S; Harley EH
Int J Pediatr Otorhinolaryngol; 2019 Feb; 117():138-142. PubMed ID: 30579068
[TBL] [Abstract][Full Text] [Related]
25. Ewing sarcoma: investigational mono- and combination therapies in clinical trials.
Gartrell J; Rodriguez-Galindo C
Expert Opin Investig Drugs; 2021 Jun; 30(6):653-663. PubMed ID: 33870845
[TBL] [Abstract][Full Text] [Related]
26. Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma.
Jain K; Henrich IC; Quick L; Young R; Mondal S; Oliveira AM; Blobel GA; Chou MM
Cancer Res Commun; 2023 Aug; 3(8):1615-1627. PubMed ID: 37615015
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
28. IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.
Lissat A; Joerschke M; Shinde DA; Braunschweig T; Meier A; Makowska A; Bortnick R; Henneke P; Herget G; Gorr TA; Kontny U
BMC Cancer; 2015 Jul; 15():552. PubMed ID: 26215971
[TBL] [Abstract][Full Text] [Related]
29. An immune-related gene signature for determining Ewing sarcoma prognosis based on machine learning.
Ren EH; Deng YJ; Yuan WH; Wu ZL; Zhang GZ; Xie QQ
J Cancer Res Clin Oncol; 2021 Jan; 147(1):153-165. PubMed ID: 32968877
[TBL] [Abstract][Full Text] [Related]
30. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
31. Precision medicine in Ewing sarcoma: a translational point of view.
Gargallo P; Juan A; Yáñez Y; Dolz S; Segura V; Castel V; Cañete A
Clin Transl Oncol; 2020 Sep; 22(9):1440-1454. PubMed ID: 32026343
[TBL] [Abstract][Full Text] [Related]
32. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
33. What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group - EWING1.
Becker RG; Gregianin LJ; Galia CR; Jesus-Garcia Filho R; Toller EA; Badell G; Nakagawa SA; David A; Baptista AM; Yonamime ES; Serafini OA; Penna V; Santos JFC; Brunetto AL;
BMC Cancer; 2017 Jun; 17(1):420. PubMed ID: 28619077
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome.
Delaplace M; Lhommet C; de Pinieux G; Vergier B; de Muret A; Machet L
Br J Dermatol; 2012 Apr; 166(4):721-6. PubMed ID: 22098102
[TBL] [Abstract][Full Text] [Related]
35. [Ewing sarcoma of the bone. Multidisciplinary approach and oncological results in 88 patients].
Sanchez-Saba JE; Abrego MO; Albergo JI; Farfalli GL; Aponte-Tinao LA; Ayerza MA; Cayol F; Streitenberger P; Risk MR; Roitman PD
Medicina (B Aires); 2020; 80(1):23-30. PubMed ID: 32044738
[TBL] [Abstract][Full Text] [Related]
36. Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy.
Kreyer J; Ranft A; Timmermann B; Juergens H; Jung S; Wiebe K; Boelling T; Schuck A; Vieth V; Streitbuerger A; Hardes J; Heinemann M; Dirksen U
Pediatr Blood Cancer; 2018 Dec; 65(12):e27384. PubMed ID: 30084137
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.
Ahrens S; Hoffmann C; Jabar S; Braun-Munzinger G; Paulussen M; Dunst J; Rübe C; Winkelmann W; Heinecke A; Göbel U; Winkler K; Harms D; Treuner J; Jürgens H
Med Pediatr Oncol; 1999 Mar; 32(3):186-95. PubMed ID: 10064186
[TBL] [Abstract][Full Text] [Related]
38. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
39. Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma.
Redini F; Heymann D
Front Oncol; 2015; 5():279. PubMed ID: 26779435
[TBL] [Abstract][Full Text] [Related]
40. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?
Redini F; Odri GA; Picarda G; Gaspar N; Heymann MF; Corradini N; Heymann D
Expert Opin Emerg Drugs; 2013 Sep; 18(3):339-52. PubMed ID: 23957761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
